Share

August 2021; 11 (4) Research

Achieving Life Milestones in Duchenne/Becker Muscular Dystrophy

A Retrospective Analysis

Andrew Donaldson, Debra Guntrum, Emma Ciafaloni, Jeffrey Statland
First published September 23, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000970
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
121

Share

Article Information

vol. 11 no. 4 311-317
DOI: 
https://doi.org/10.1212/CPJ.0000000000000970
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received December 30, 2019
  • Accepted July 30, 2020
  • First Published September 23, 2020.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Andrew Donaldson,
    2. Debra Guntrum, NP,
    3. Emma Ciafaloni, MD and
    4. Jeffrey Statland, MD
  1. Andrew Donaldson,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Debra Guntrum, NP,
    3. Scientific Advisory Boards:

    1. (1)AveXis (2)Biogen (3)Sarepta (4)PTC

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen honoraria for nursing advisory board (2) PTC honoraria for nursing advisory board

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Emma Ciafaloni, MD and
    4. Scientific Advisory Boards:

    1. Sarepta Avexis Biogen Santhera PTC Wave Sanofi

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. MedLink

    Patents:

    1. NONE

    Publishing Royalties:

    1. Oxford Press

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Center Disease Control Prevention: "Surveillance and Epidemiological Research of Duchenne and Becker Muscular Dystrophy"

    Speakers' Bureaus:

    1. Biogen

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Sarepta, PTC, Santhera, Orphazyme: clinical trial support

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jeffrey Statland, MD
    5. Scientific Advisory Boards:

    1. 1) Advisory Board - Fulcrum 2) Advisory Board - Sarepta 3) Advisory Board - Acceleron 4) Advisory Board - Dyne

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Acceleron 2) Fulcrum 3) Strongbridge 4) Dyne 5) Sarepta 6) Avidity

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. 1) NINDS 5U01NS101944-02, Role co-PI, 6/2017-present 2) NCATS R21TR003184-01, Role co-PI, 6/2020-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1) FSH Society Grant - FSHD clinical trial research network 2) MDA Infrastructure Grant - 06/2018 - present 3) Friends of FSH Research - MOVE FSHD study

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. University of Kansas Medical Center (AD, JS); and University of Rochester Medical Center (DG, EC), NY.
  1. Correspondence
    Dr. Statland JStatland{at}kumc.edu
View Full Text

Article usage

Article usage: September 2020 to August 2023

AbstractFullPdfSource
Sep 20206402Highwire
Oct 20209506Highwire
Nov 20205904Highwire
Dec 20209506Highwire
Jan 20214405Highwire
Feb 20213207Highwire
Mar 20213906Highwire
Apr 20212303Highwire
May 20211905Highwire
Jun 20212803Highwire
Jul 20212609Highwire
Aug 20216812020Highwire
Sep 202123864Highwire
Oct 202113317Highwire
Nov 20215101Highwire
Dec 20215600Highwire
Jan 20225901Highwire
Feb 20225922Highwire
Mar 20226143Highwire
Apr 20224001Highwire
May 20223501Highwire
Jun 20222910Highwire
Jul 20226511Highwire
Aug 20225622Highwire
Sep 202210311Highwire
Oct 20224233Highwire
Nov 20226613Highwire
Dec 20222600Highwire
Jan 20235611Highwire
Feb 20234521Highwire
Mar 20232602Highwire
Apr 20235701Highwire
May 20232800Highwire
Jun 20232122Highwire
Jul 20233106Highwire
Aug 20231732Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles